Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting

Executive Summary

Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.

You may also be interested in...



Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC

Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.

Can’t Win Them All: Two Merck Oncology Trials Fail

The company stopped a study of Lynparza in colorectal cancer for futility and announced a study of Keytruda/chemoradiation in head-and-neck cancer didn’t meet its primary endpoint.

Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel